{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:55:37Z","timestamp":1767178537882,"version":"build-2238731810"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T00:00:00Z","timestamp":1502323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000098","name":"NIH Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0182879","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T13:42:00Z","timestamp":1502372520000},"page":"e0182879","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":18,"title":["A systematic review and meta-analysis of preclinical trials testing anti-toxin therapies for B. anthracis infection: A need for more robust study designs and results"],"prefix":"10.1371","volume":"12","author":[{"given":"Wanying","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lernik","family":"Ohanjandian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junfeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xizhong","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dante","family":"Suffredini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Welsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5470-4677","authenticated-orcid":true,"given":"Peter Q.","family":"Eichacker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2017,8,10]]},"reference":[{"key":"ref1","first-page":"954","article-title":"Clinical management of potential bioterrorism-related conditions","volume":"368","author":"AA Adalja","year":"2009","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3201\/eid0706.010604","article-title":"Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States","volume":"7","author":"JA Jernigan","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.3201\/eid0810.020353","article-title":"Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings","volume":"8","author":"DB Jernigan","year":"2002","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"ref4","doi-asserted-by":"crossref","first-page":"e130687","DOI":"10.3201\/eid2002.130687","article-title":"Centers for disease and control prevention expert panel meetings on prevention and treatment of anthrax in adults","volume":"20","author":"KA Hendricks","year":"2014","journal-title":"Emerg Infect Dis"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6404a1","article-title":"Clinical framework and medical countermeasure use during an anthrax mass-casualty incident","volume":"64","author":"WA Bower","year":"2015","journal-title":"MMWR Recomm Rep"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/13543784.2015.1041587","article-title":"An overview of investigational toxin-directed therapies for the adjunctive management of Bacillus anthracis infection and sepsis","volume":"24","author":"L Ohanjanian","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s40265-016-0577-0","article-title":"Obiltoxaximab: First global approval","volume":"76","author":"SL Greig","year":"2016","journal-title":"Drugs"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1089\/hs.2015.0032","article-title":"Antitoxin treatment of inhalation anthrax: a systematic review","volume":"13","author":"E Huang","year":"2015","journal-title":"Health Secur"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.3201\/eid2301.160608","article-title":"Analysis of anthrax immune globulin intravenous with antimicrfobial treatment in injection drug users, Scotland, 2009\u20132010","volume":"23","author":"X Cui","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"R DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"JP Higgins","year":"2002","journal-title":"Statistics in medicine"},{"key":"ref12","unstructured":"R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.R-project.org\/\" xlink:type=\"simple\">http:\/\/www.R-project.org\/<\/ext-link>."},{"key":"ref13","unstructured":"Guido Schwarzer (2015). meta: General Package for Meta-Analysis. R package version 4.1\u20130.<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/CRAN.R-project.org\/package=meta\" xlink:type=\"simple\">http:\/\/CRAN.R-project.org\/package=meta<\/ext-link>"},{"issue":"3","key":"ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"W. Viechtbauer","year":"2010","journal-title":"Journal of Statistical Software"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"270","DOI":"10.7326\/0003-4819-144-4-200602210-00009","article-title":"Systematic review: a century of inhalational anthrax cases from 1900 to 2005","volume":"144","author":"JE Holty","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/infdis\/jir834","article-title":"Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines","volume":"205","author":"AV Barochia","year":"2012","journal-title":"J Infect Dis"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s40635-015-0043-4","article-title":"Raxibacumab augments hemodynamic support and improves outcome during shock with B. anthracis edema toxin alone or together with lethal toxin in canines","volume":"3","author":"KE Remy","year":"2015","journal-title":"Intensive Care Med Exp"},{"key":"ref18","first-page":"H1440","article-title":"Antibiotics versus cardiovascular support in a canine model of human sepsis shock","volume":"259","author":"C Natanson","year":"1990","journal-title":"Am J Physiol"},{"key":"ref19","first-page":"486","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016","volume":"45","author":"A Rhodes","year":"2017","journal-title":"Intensive Care Med"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1007\/s00134-011-2324-z","article-title":"The individual survival benefits of tumor necrosis factor soluble receptor and fluid administration are not additive in a rat sepsis model","volume":"37","author":"P Qiu","year":"2011","journal-title":"Intensive Care Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1128\/IAI.00170-10","article-title":"Inflammatory cytokine response to Bacillus anthracis peptidoglycan requires phagocytosis and lysosomal trafficking","volume":"78","author":"JK Iyer","year":"2010","journal-title":"Infect Immun"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/jcmm.12075","article-title":"The sepsis model: an emerging hypothesis for the lethality of inhalation anthrax","volume":"17","author":"KM Coggeshall","year":"2013","journal-title":"J Cell Mol Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/infdis\/jit247","article-title":"Bacillus anthracis cell wall peptidoglycan but not lethal or edema toxins produces changes consistent disseminated intravascular coagulation in a rat model","volume":"208","author":"P Qiu","year":"2013","journal-title":"J Infect Dis"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e17921","DOI":"10.1371\/journal.pone.0017921","article-title":"Bacillus anthracis protease InhA increases blood brain barrier permeability and contributes to cerebral hemorrhage","volume":"6","author":"DV Mukherjee","year":"2011","journal-title":"PLoS One"},{"key":"ref25","article-title":"Product development under the animal rule; guidance for industry","year":"2015","journal-title":"October"},{"key":"ref26","unstructured":"US Dept. of HHS FDA. Raxibacumab injection prescribing information. December 2012. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125349s000lbl.pdf\" xlink:type=\"simple\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/125349s000lbl.pdf<\/ext-link>. Accessed July 16, 2017"},{"key":"ref27","unstructured":"US Dept. of HHS FDA. Anthim (obiltoxaximab) injection prescribing information. March 2016. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125509lbl.pdf\" xlink:type=\"simple\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125509lbl.pdf<\/ext-link>. Accessed July 16, 2017."},{"key":"ref28","unstructured":"Roos R. Anthrax countermeasures better than in 2001, but work remains. October 18, 2011. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.cidrap.umn.edu\/news\u2026\/10\/anthrax-countermeasures-better-2001-work-remains\" xlink:type=\"simple\">www.cidrap.umn.edu\/news\u2026\/10\/anthrax-countermeasures-better-2001-work-remains<\/ext-link>. Accessed March 21, 2017"},{"key":"ref29","unstructured":"US Government adds two drugs that treat inhalational anthrax to Strategic National Stockpile. November 14, 2015. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/outbreaknewstoday.com\/us-government-adds-two-drugs-that-treat-inhalational-anthrax-to-strategic-national-stockpile-38354\/\" xlink:type=\"simple\">http:\/\/outbreaknewstoday.com\/us-government-adds-two-drugs-that-treat-inhalational-anthrax-to-strategic-national-stockpile-38354\/<\/ext-link>. Accessed March 21, 2017"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0189239","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T00:00:00Z","timestamp":1512345600000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0182879","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T10:14:10Z","timestamp":1540030450000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0182879"}},"subtitle":[],"editor":[{"given":"Nicholas J","family":"Mantis","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2017,8,10]]},"references-count":29,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2017,8,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0182879","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,10]]}}}